Background: Diazabicyclooctanes, e.g. avibactam and relebactam, are a new class of b-lactamase inhibitors. Their spectrum includes AmpC enzymes, but it is important to understand whether they also induce these enzymes.
Introduction
Diazabicyclooctanes (DBOs), such as avibactam and relebactam, inhibit AmpC b-lactamases. 1, 2 It is of interest to know whether they also induce these enzymes, both to answer the question of whether a non-b-lactam can induce and because induction hypothetically might lead to antagonism if the DBO is combined with a weak-inducer b-lactam and the AmpC enzyme had mutated so as to become resistant to inhibition by DBOs. On this basis we examined the AmpC inducer behaviour of avibactam and relebactam for Enterobacter cloacae, Citrobacter freundii and Pseudomonas aeruginosa, as the species where these enzymes are most important. Because it is impracticable to measure b-lactamase specific activity when an inducer is also an inhibitor, we adopted an alternative approach, using RT-PCR to measure the levels of AmpCencoding mRNA.
Materials and methods

Organisms
The test strains were reference submissions to PHE, collected in 2010-12, or were from an earlier UK survey. 3 They comprised five isolates each of E. cloacae, C. freundii and P. aeruginosa. The E. cloacae and C. freundii strains were confirmed as AmpC inducible, based on being susceptible (MICs 1 mg/L) to cefotaxime and ceftazidime, but resistant to cefoxitin, with antagonism of cefotaxime and ceftazidime by cefoxitin in double disc tests; 4 P. aeruginosa isolates were AmpC inducible based on being susceptible to carbenicillin (MIC 128 mg/L) and ceftazidime (MIC 2 mg/L), with antagonism of ceftazidime by imipenem in double disc tests. All the strains were susceptible to imipenem at CLSI breakpoints; MICs of avibactam and relebactam ranged from 16 to .128 mg/L. 
Antibiotics
RT-PCR assay
Primers (Sigma) and probes (Applied Biosystems, Life Technologies, Paisley, UK) were as detailed in Table 1 . Probes were labelled with either 6-FAM (6-carboxy-fluorescein) or VIC V R at the 5 0 end, and with TAMRA (6-carboxytetramethyl-rhodamine) at the 3 0 end. RT-PCR was performed using the TaqMan RNA-to-C T 1-Step Kit (Applied Biosystems). Each reaction was prepared in a 20 lL volume and contained 1 % TaqMan RT-PCR mix, 0.5 lL of RT enzyme mix, 500 nM of each primer, 250 nM of each probe and 1 lL of RNA template. The RT-PCR consisted of a reverse transcription step for 15 min at 48 C, followed by an activation step of 10 min at 95 C and 40 cycles of denaturation for 15 s at 95 C and annealing/extension for 1 min at 60 C. The absence of genomic DNA contamination was verified for each RNA preparation by running RT-PCR without reverse transcriptase. The reactions and data analyses were conducted using the Fast Real-Time PCR System 7500 (Applied Biosystems). Reactions were performed in triplicate. cDNA derived from expression of ampC was measured relative to that arising from housekeeping genes, namely guaA in P. aeruginosa, rpoB in C. freundii and rspL in E. cloacae, thereby correcting for differences in the amount of starting material. These standardized estimates of ampC transcript-derived cDNA were then re-standardized against ampC transcript-derived cDNA in the non-induced culture at the same timepoint. Relative quantification was carried out by using the 2 #DDCt method, where the Ct value is defined as the first PCR cycle at which the fluorescence is above the threshold value of 0.2, as recommended by the thermal cycler instrument manufacturer. 6 An induction ratio was thus defined as: (time t ampC signal Ä time t housekeeping signal)/(time 0 ampC signal Ä time 0 housekeeping signal), with results averaged across the three replicate mixtures.
Results and discussion
Susceptibility
The test strains-which were confirmed as AmpC inducible-were all susceptible to ceftazidime and imipenem in the absence of DBOs (Table 2 ). C. freundii H121940571 was narrowly resistant to ceftaroline (MIC 1 mg/L versus a breakpoint of 0.5 mg/L); all the P. aeruginosa strains tested (5/5) also had inherent resistance to ceftaroline, as is typical of the species. Addition of DBOs caused small reductions in the MICs of the partner b-lactams (Table 2) , typically 2-to 4-fold. No antagonism was seen.
Induction assays
RT-PCR-based induction assays (Table 3 ) proved less precise than those based on measurement of b-lactamase specific activity (see, for example, Livermore 7 ), no doubt owing to the much more complex multi-step method needed for estimation, and perhaps also because mRNA persists more briefly than induced AmpC enzyme. This variability is reflected in the scatter of induction ratios, from 0.1 to 32, for the t 0 estimates, where values around unity would be expected. Moreover, assays for avibactam and relebactam were run several months apart, each time with cefoxitin as a control, and, whilst both sets of experiments showed that cefoxitin induced strongly, there was considerable inter-run scatter for results with this cephamycin, without clear systematic bias (not shown). On this basis we only considered induction significant if induction ratios .10 were obtained for at least two successive timepoints, whilst 'strong' induction was taken as one ratio .100, with a ratio .10 at the preceding or subsequent timepoint. Based upon these criteria, cefoxitin counted as an inducer for all 15 strains and a strong inducer for all except one C. freundii and one P. aeruginosa. The rises in AmpC mRNA were greatest and most prolonged at the highest cefoxitin concentration (32 mg/L), but induction was often also apparent with the drug at 4 mg/L, confirming a concentration-response relationship. These data are in keeping with a considerable body of data from conventional induction assays. 7 Relebactam, at the other extreme, gave no convincing evidence of induction for any strain, with only two isolated instances of ratios .10, neither of them supported by raised ratios at adjacent timepoints or with any relation to concentration. Avibactam had more variable behaviour, meeting our definitions of a strong inducer for 2/5 E. cloacae and 2/5 P. aeruginosa at the highest avibactam concentration (32 mg/L). However, there was no significant induction for the other 11/15 strains, including all the C. freundii, or at lower avibactam concentrations. Miossec et al.
by several researchers to bind to PBP2 of Enterobacteriaceae. [9] [10] [11] Linking these observations to inducer power is, however, speculative. The higher MICs of relebactam may relate to uptake rather than PBP affinity; moreover, the precise links between PBP inhibition and the perturbation of the peptidoglycan fragment recycling that regulates AmpC induction 12 remain elusive, perhaps because PBP assays only detect the formation of covalent adducts, not other interactions. Clavulanic acid, which likewise binds Livermore et al. 13 is an AmpC inducer for some strains, 14 but mecillinam, which also binds this target, has little inducer power.
15 PBP4 interactions, as found for avibactam by one group, 10 have been suggested to be a correlate of AmpC induction in P. aeruginosa.
16
Any practical significance of AmpC induction by avibactam is doubtful. Significant induction with avibactam, where it occurred, was only seen with 32 mg/L avibactam, a concentration around the C max following a standard 500 mg dosage and therefore far above the mean inter-dose level. [17] [18] [19] Moreover, induced enzyme should be inhibited, and ceftazidime/avibactam is active against strains with derepressed AmpC, producing more enzyme than is ever likely to be induced. 1, 2 The only circumstances in which this induction might become clinically significant would be if the AmpC enzyme (i) mutated to lose affinity for avibactam and (ii) remained inducible. Avibactam-induced enzyme might then attack its partner cephalosporin. Protein sequence changes within AmpC, arising via mutation, can engender resistance to ceftaroline/avibactam and ceftazidime/avibactam 20 (also PHE, data on file); however, these seem more likely to be selected, if at all, once the enzyme expression is already derepressed, not when it remains inducible. We therefore consider the present data largely of academic interest, in showing that a non-b-lactam can act as an AmpC inducer as well as inhibiting b-lactamases and targeting PBP2.
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